SEC Tracker
Get the app

Hepion Pharmaceuticals HEPA

Hepion Pharmaceuticals acquires GLS

Form
8-K
Filed
Importance
Routine
  1. Acquired Gravitas Life Sciences for $2M cash and 25M shares
  2. GLS becomes wholly owned subsidiary
  3. Transaction involved related parties
  4. FDA approved IND for GV104 in 2023

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Hepion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. China Foods Holdings CFOO public float $864K, Jun 30, 2025
  2. Mosaic ImmunoEngineering CPMV public float $856K, Jun 30, 2025
  3. Twinlab Consolidated Holdings TLCC public float $1M, Jun 30, 2025
  4. Regen BioPharma RGBP public float $1M, Mar 31, 2025, over 18 months old
  5. Nutra Pharma NPHC public float $703K, Jun 30, 2025